Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients

Hematol Oncol. 2013 Dec;31(4):223-4. doi: 10.1002/hon.2049. Epub 2013 Apr 26.

Authors

Pier Luigi Zinzani¹, Cinzia Pellegrini, Enrico Derenzini, Lisa Argnani, Stefano Pileri

Affiliation

¹ Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy. pierluigi.zinzani@unibo.it.

PMID: 23620452
DOI: 10.1002/hon.2049

No abstract available

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Combined Modality Therapy
Disease-Free Survival
Hematopoietic Stem Cell Transplantation
Humans
Lenalidomide
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / surgery
Maintenance Chemotherapy
Middle Aged
Remission Induction
Rituximab
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives
Transplantation, Autologous
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Rituximab
Thalidomide
Lenalidomide